Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in CAYA
NCT07043894Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2025
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Proportion of patients achieving platelet count recovery at 3 weeks. Started Dec 2025; status: recruiting.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT07043894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043894.